0001144204-15-000194.txt : 20150102 0001144204-15-000194.hdr.sgml : 20150102 20150102182920 ACCESSION NUMBER: 0001144204-15-000194 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20141230 FILED AS OF DATE: 20150102 DATE AS OF CHANGE: 20150102 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TG THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001001316 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 363898269 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 787 SEVENTH AVENUE CITY: NEW YORK STATE: NY ZIP: 10019 BUSINESS PHONE: (212) 554-4484 MAIL ADDRESS: STREET 1: 787 SEVENTH AVENUE CITY: NEW YORK STATE: NY ZIP: 10019 FORMER COMPANY: FORMER CONFORMED NAME: MANHATTAN PHARMACEUTICALS INC DATE OF NAME CHANGE: 20030310 FORMER COMPANY: FORMER CONFORMED NAME: ATLANTIC TECHNOLOGY VENTURES INC DATE OF NAME CHANGE: 20000330 FORMER COMPANY: FORMER CONFORMED NAME: ATLANTIC PHARMACEUTICALS INC DATE OF NAME CHANGE: 19960703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WEISS MICHAEL S CENTRAL INDEX KEY: 0001038977 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32639 FILM NUMBER: 15502229 MAIL ADDRESS: STREET 1: 750 LEXINGTON AVE CITY: NEW YORK STATE: NY ZIP: 10022 4 1 v397948_4.xml OWNERSHIP DOCUMENT X0306 4 2014-12-30 0 0001001316 TG THERAPEUTICS, INC. TGTX 0001038977 WEISS MICHAEL S 3 COLUMBUS AVE, 15TH FLOOR NEW YORK NY 10019 1 1 1 0 See Remarks COMMON STOCK 2014-12-30 4 A 0 268603 0 A 8389376 D Reflects a grant of restricted shares that will vest according to the following schedule: 25% on January 1, 2018; 25% on January 1, 2019; and 50% on the later to occur of: (a) the date that the Company's Market Capializaion is $100 million greater than the Market Capitalization on the date of the grant and (b) the 5th anniversary of the date of the grant. Includes shares of restricted Common Stock, which vest over various time periods. Includes 33,334 warrants to purchase Common Stock at $2.25, exercisable through December 31, 2016. Finally, also included in Mr. Weiss' beneficial ownership are 4,524,560 shares of Common Stock issued to Opus Point Partners, LLC, of which Mr. Weiss is a co-founder, managing partner, and principal and beneficially owns a 50% interest. Executive Chairman, Interim CEO and President /s/ Michael Weiss 2015-01-02